Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
about
Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situBioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trialSignatures of breast cancer metastasis at a glanceA systematic comparison of copy number alterations in four types of female cancerGlobal array-based transcriptomics from minimal input RNA utilising an optimal RNA isolation process combined with SPIA cDNA probesEpigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma.Discovering combinatorial interactions in survival dataMicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.ASPP: a new family of oncogenes and tumour suppressor genes.Three methods for optimization of cross-laboratory and cross-platform microarray expression data.Proteomics in clinical trials and practice: present uses and future promise.Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repressionMicrofluidic leukocyte isolation for gene expression analysis in critically ill hospitalized patientsGrowth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Equivalence of MammaPrint array types in clinical trials and diagnostics.Fool's gold, lost treasures, and the randomized clinical trial.The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues reveals a link to tumor progression.Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patientsASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?Partial PTEN deletion is linked to poor prognosis in breast cancerLow E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyGene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.8p deletion is strongly linked to poor prognosis in breast cancer.Network analysis of gene lists for finding reproducible prognostic breast cancer gene signatures.Prognostic values of apoptosis-stimulating P53-binding protein 1 and 2 and their relationships with clinical characteristics of esophageal squamous cell carcinoma patients: a retrospective studyGrb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceCan clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility studyIs adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer.
P2860
Q26864448-51CE5FAD-2AB4-461E-AD3E-05C3FBE8A05FQ27015838-88E5D070-02DF-444E-9533-436FE64C9163Q28071451-D44615F0-DFB2-4DD0-AA1C-F496AAB01F2CQ28394747-3B3783CF-A7DD-43A3-8D54-A4E943E4A303Q28741725-D96CA4DE-84E1-4621-A128-B405CE60789EQ30157007-EC1B7728-3B90-4D06-811D-19672511B2F3Q30557494-7EDF05EA-E000-42E9-808D-D8665E99EAD1Q30591772-0B078923-864C-4CF0-A6BB-9D4F41ED27F5Q31090644-594425F8-893F-473E-8F37-C95795B21D3BQ31111559-E8C6DC3F-3A61-40EA-AD1A-AF0DDFECFFC1Q33245305-07EB3952-DB83-4950-88B9-58C75AEC4008Q33294142-D7CDF572-C5C7-4B00-BFF6-1A1F5F898297Q33528957-1241EE91-5B92-4E22-8A93-A3C2F2B706E2Q33570300-F5510694-90BE-4479-8205-75ECFC63E5D2Q33676758-C7797EE6-48C6-417F-99A6-67C22A19ED00Q34190743-3A6B89A4-1F6D-4940-A9C3-9E866D46B865Q34296481-D0ADB67F-491B-488F-BFEB-FBE1E5F16F1EQ34431985-3E0818D4-6BD4-4AA0-8077-9A2302510099Q34519347-1089A19A-CB55-46E8-92FA-8A7BC626D265Q34669260-A2DAFF17-8E14-4BC0-BF0B-B500A003A505Q35067415-DB5DFC4B-23EC-4ABB-BC38-C3BB6A870C7AQ35146561-F86A0A0D-29B9-4466-A7A8-67DD26E5C6F4Q35167133-C2E2C0D8-5151-4D9E-BE7B-B98DFB71C22BQ35206500-5EA302AE-1E8A-40EB-89EE-1D267D594533Q35602598-F87BA854-72EE-49B6-8E5A-8D4F2A564E18Q35622059-E97E0DCB-E9A5-416C-A1A8-8907DB1700FCQ35870069-9E7EB482-E392-4C9E-99F1-5026F88C6A16Q35906318-E936E744-76FF-40ED-A313-25784A8BD9EAQ35915708-A981A55B-DAAB-48EC-8539-C4B50A5A41B8Q36055953-C4628727-9B51-46A8-9F9E-5270A118E90FQ36110190-878BC94D-2B57-421C-86EC-CD31F9C2E555Q36214952-4C038BE0-3049-470D-AE51-97BF8DCD406CQ36254419-AB30122E-684F-45AD-ACAE-1B69752E77EDQ36254626-B2F4DA08-26CB-4162-BDF7-B98E45D8BAB7Q36261762-DBC3E14C-CAF2-4C99-BDD2-2C51C38E6BCDQ36462893-91529A1B-9C57-4982-AF46-74E359F01608Q36643030-1DF3160F-3511-4279-B2AA-FC3CB2B51477Q36659104-7B555653-5C53-40DC-9CD2-70A018A06F31Q36816034-508FB81A-2AEE-4840-A510-FFFBCE1C3CB8Q37031561-9EB01390-E4CC-4FBD-91AB-105007530CC3
P2860
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tumor gene expression and prog ...... or more positive lymph nodes.
@ast
Tumor gene expression and prog ...... or more positive lymph nodes.
@en
type
label
Tumor gene expression and prog ...... or more positive lymph nodes.
@ast
Tumor gene expression and prog ...... or more positive lymph nodes.
@en
prefLabel
Tumor gene expression and prog ...... or more positive lymph nodes.
@ast
Tumor gene expression and prog ...... or more positive lymph nodes.
@en
P2093
P1476
Tumor gene expression and prog ...... or more positive lymph nodes.
@en
P2093
Bita Tabesh
Joffre Baker
Juan-Miguel Mosquera
Maureen Cronin
Mei-Lan Liu
Melody A Cobleigh
Michael G Walker
Pincas Bitterman
Russell Borchik
Steven Shak
P304
P356
10.1158/1078-0432.CCR-05-0735
P407
P433
P577
2005-12-01T00:00:00Z